Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon Inks Development Deal for Chronic Kidney Disease Dx

NEW YORK (GenomeWeb) – Metabolon announced that it has partnered with Johns Hopkins University and Tufts Medical Center to develop and clinically validate a new test for diagnosing chronic kidney disease.

The test, called accuGFR, will be based on previous work by the collaborators evaluating hundreds of patient samples to verify novel metabolite markers of glomerular filtration rate (GFR) to assess kidney function.

Under the terms of their deal, the partners will create a blood-based test based on these markers and compare its performance in large and well-characterized patient cohorts against the current gold standard — measured GFR — which involves tracking urinary or plasma clearance of exogenous filtration markers.

Additional terms of the arrangement were not disclosed.